Dynavax Technologies Corporation
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also devel… Read more
Dynavax Technologies Corporation (DVAX) - Net Assets
Latest net assets as of September 2025: $534.14 Million USD
Based on the latest financial reports, Dynavax Technologies Corporation (DVAX) has net assets worth $534.14 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($946.51 Million) and total liabilities ($412.37 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $534.14 Million |
| % of Total Assets | 56.43% |
| Annual Growth Rate | N/A |
| 5-Year Change | 916.81% |
| 10-Year Change | 219.01% |
| Growth Volatility | 211.75 |
Dynavax Technologies Corporation - Net Assets Trend (2000–2024)
This chart illustrates how Dynavax Technologies Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Dynavax Technologies Corporation (2000–2024)
The table below shows the annual net assets of Dynavax Technologies Corporation from 2000 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $596.80 Million | -4.06% |
| 2023-12-31 | $622.07 Million | +7.07% |
| 2022-12-31 | $581.01 Million | +161.28% |
| 2021-12-31 | $222.37 Million | +278.88% |
| 2020-12-31 | $58.69 Million | +608.00% |
| 2019-12-31 | $8.29 Million | -86.85% |
| 2018-12-31 | $63.06 Million | -68.40% |
| 2017-12-31 | $199.55 Million | +123.71% |
| 2016-12-31 | $89.20 Million | -52.32% |
| 2015-12-31 | $187.08 Million | +86.18% |
| 2014-12-31 | $100.48 Million | -46.06% |
| 2013-12-31 | $186.29 Million | +62.24% |
| 2012-12-31 | $114.83 Million | +14.96% |
| 2011-12-31 | $99.88 Million | +91.67% |
| 2010-12-31 | $52.11 Million | +717.30% |
| 2009-12-31 | $6.38 Million | -60.53% |
| 2008-12-31 | $16.16 Million | -58.71% |
| 2007-12-31 | $39.13 Million | -50.51% |
| 2006-12-31 | $79.07 Million | +6.33% |
| 2005-12-31 | $74.36 Million | +24.20% |
| 2004-12-31 | $59.88 Million | +204.68% |
| 2003-12-31 | $-57.20 Million | -1.47% |
| 2002-12-31 | $-56.37 Million | -63.79% |
| 2001-12-31 | $-34.42 Million | -91.22% |
| 2000-12-31 | $-18.00 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Dynavax Technologies Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 87771200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $125.00K | 0.02% |
| Other Comprehensive Income | $-4.72 Million | -0.79% |
| Other Components | $1.50 Billion | 252.12% |
| Total Equity | $596.80 Million | 100.00% |
Dynavax Technologies Corporation Competitors by Market Cap
The table below lists competitors of Dynavax Technologies Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Trump Media & Technology Group Corp.
NASDAQ:DJT
|
$1.56 Billion |
|
CNNC Hua Yuan Titanium Dioxide Co Ltd
SHE:002145
|
$1.56 Billion |
|
Netwealth Group Ltd
AU:NWL
|
$1.56 Billion |
|
Talos Energy
NYSE:TALO
|
$1.56 Billion |
|
Pitney Bowes Inc
NYSE:PBI
|
$1.56 Billion |
|
AVIC (Chengdu) UAS Co. Ltd. A
SHG:688297
|
$1.55 Billion |
|
PNB Housing Finance Limited
NSE:PNBHOUSING
|
$1.55 Billion |
|
SHANGHAI JUNSHI BIO YC1
F:8SJ
|
$1.55 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Dynavax Technologies Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 622,072,000 to 596,799,000, a change of -25,273,000 (-4.1%).
- Net income of 27,309,000 contributed positively to equity growth.
- Share repurchases of 100,000,000 reduced equity.
- Other comprehensive income decreased equity by 2,614,000.
- Other factors increased equity by 50,032,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $27.31 Million | +4.58% |
| Share Repurchases | $100.00 Million | -16.76% |
| Other Comprehensive Income | $-2.61 Million | -0.44% |
| Other Changes | $50.03 Million | +8.38% |
| Total Change | $- | -4.06% |
Book Value vs Market Value Analysis
This analysis compares Dynavax Technologies Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.46x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2000-12-31 | $-152.15 | $15.50 | x |
| 2001-12-31 | $-229.75 | $15.50 | x |
| 2002-12-31 | $-331.40 | $15.50 | x |
| 2003-12-31 | $-398.96 | $15.50 | x |
| 2004-12-31 | $28.26 | $15.50 | x |
| 2005-12-31 | $28.70 | $15.50 | x |
| 2006-12-31 | $23.83 | $15.50 | x |
| 2007-12-31 | $7.75 | $15.50 | x |
| 2008-12-31 | $3.40 | $15.50 | x |
| 2009-12-31 | $1.58 | $15.50 | x |
| 2010-12-31 | $6.32 | $15.50 | x |
| 2011-12-31 | $7.98 | $15.50 | x |
| 2012-12-31 | $6.74 | $15.50 | x |
| 2013-12-31 | $9.49 | $15.50 | x |
| 2014-12-31 | $3.82 | $15.50 | x |
| 2015-12-31 | $5.69 | $15.50 | x |
| 2016-12-31 | $2.32 | $15.50 | x |
| 2017-12-31 | $3.79 | $15.50 | x |
| 2018-12-31 | $1.01 | $15.50 | x |
| 2019-12-31 | $0.12 | $15.50 | x |
| 2020-12-31 | $0.58 | $15.50 | x |
| 2021-12-31 | $1.67 | $15.50 | x |
| 2022-12-31 | $3.85 | $15.50 | x |
| 2023-12-31 | $4.83 | $15.50 | x |
| 2024-12-31 | $4.48 | $15.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Dynavax Technologies Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.58%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.85%
- • Asset Turnover: 0.28x
- • Equity Multiplier: 1.65x
- Recent ROE (4.58%) is above the historical average (-146.36%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 0.00% | 0.00% | 0.00x | 0.00x | $-24.92 Million |
| 2001 | 0.00% | -780.50% | 0.16x | 0.00x | $-14.97 Million |
| 2002 | 0.00% | -1264.05% | 0.05x | 0.00x | $-12.40 Million |
| 2003 | 0.00% | -2100.73% | 0.03x | 0.00x | $-10.16 Million |
| 2004 | -26.67% | -107.82% | 0.20x | 1.23x | $-21.96 Million |
| 2005 | -27.64% | -140.26% | 0.18x | 1.08x | $-27.99 Million |
| 2006 | -67.55% | -1073.90% | 0.05x | 1.34x | $-59.76 Million |
| 2007 | -194.77% | -425.54% | 0.12x | 3.91x | $-63.05 Million |
| 2008 | -154.04% | -56.15% | 0.41x | 6.70x | $-22.18 Million |
| 2009 | -479.38% | -75.81% | 0.80x | 7.92x | $-31.20 Million |
| 2010 | -109.97% | -239.28% | 0.28x | 1.62x | $-62.52 Million |
| 2011 | -48.66% | -224.84% | 0.16x | 1.34x | $-58.59 Million |
| 2012 | -60.92% | -720.08% | 0.07x | 1.22x | $-81.43 Million |
| 2013 | -35.81% | -593.01% | 0.05x | 1.10x | $-85.35 Million |
| 2014 | -90.29% | -822.35% | 0.08x | 1.38x | $-100.77 Million |
| 2015 | -57.08% | -2636.89% | 0.02x | 1.16x | $-125.50 Million |
| 2016 | -126.06% | -1018.24% | 0.10x | 1.23x | $-121.36 Million |
| 2017 | -47.68% | -29099.08% | 0.00x | 1.10x | $-115.11 Million |
| 2018 | -251.96% | -1938.27% | 0.04x | 3.34x | $-165.21 Million |
| 2019 | -1840.77% | -433.29% | 0.13x | 33.66x | $-153.43 Million |
| 2020 | -128.19% | -161.63% | 0.13x | 6.02x | $-81.11 Million |
| 2021 | 34.50% | 17.46% | 0.42x | 4.67x | $54.48 Million |
| 2022 | 50.46% | 40.56% | 0.73x | 1.70x | $235.05 Million |
| 2023 | -1.03% | -2.75% | 0.23x | 1.60x | $-68.60 Million |
| 2024 | 4.58% | 9.85% | 0.28x | 1.65x | $-32.37 Million |
Industry Comparison
This section compares Dynavax Technologies Corporation's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $580,491,146
- Average return on equity (ROE) among peers: -45.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Dynavax Technologies Corporation (DVAX) | $534.14 Million | 0.00% | 0.77x | $1.56 Billion |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $14.78 Million | -64.19% | 0.99x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $-241.47K | 0.00% | 0.00x | $603.58K |
| Aurora Cannabis Inc (ACB) | $521.74 Million | -329.21% | 0.78x | $194.64 Million |
| Acreage Holdings Inc (ACRDF) | $494.79 Million | -30.37% | 0.40x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $37.06 Million | 39.05% | 0.16x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $32.70 Million | -18.88% | 0.16x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $21.19 Million | 12.93% | 1.96x | $1.84 |
| Adcock Ingram Holdings Limited (AIHLF) | $4.54 Billion | 14.90% | 0.58x | $85.61 Million |